Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$21.08 +2.5%	$21.29	$19.00 ▼ $26.58	$2.52B	0.7	1.44 million shs	1.11 million shs
GMTX Gemini Therapeutics	$60.35 +1.0%	$56.73	$1.16 ▼ $14.10	$2.61B	-0.12	189,291 shs	349,244 shs
RXRX Recursion Pharmaceuticals	$4.94 +3.3%	$5.46	$3.79 ▼ $12.36	$2.14B	0.93	19.92 million shs	19.86 million shs
UPXI Upexi	$7.93 +13.6%	$6.05	$1.90 ▼ $22.57	$409.11M	-0.52	8.40 million shs	8.44 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+2.53%	+4.20%	-2.27%	-13.92%	+2.98%
GMTX Gemini Therapeutics	+1.75%	-1.60%	-1.63%	+26.13%	+19.62%
RXRX Recursion Pharmaceuticals	+3.35%	-14.38%	-23.17%	+21.08%	-35.17%
UPXI Upexi	+13.61%	+7.89%	+18.36%	-25.75%	+103.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.889 of 5 stars	3.6	1.0	0.0	3.9	3.4	3.3	3.8
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	2.5344 of 5 stars	3.2	1.0	0.0	0.0	3.8	2.5	0.6
UPXI Upexi	2.7689 of 5 stars	3.8	2.0	0.0	0.0	3.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	57.50% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	41.70% Upside
UPXI Upexi	3.50	Strong Buy	$15.50	95.46% Upside

Current Analyst Ratings Breakdown

Latest UPXI, GMTX, RXRX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.25	$2.51 per share	8.40	$6.99 per share	3.02
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
RXRX Recursion Pharmaceuticals	$64.51M	33.24	N/A	N/A	$2.12 per share	2.33
UPXI Upexi	$26M	17.88	N/A	N/A	$6.24 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.78	9.90	0.84	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest UPXI, GMTX, RXRX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
GMTX Gemini Therapeutics	N/A	71.49	71.49
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GMTX Gemini Therapeutics	75.42%
RXRX Recursion Pharmaceuticals	89.06%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GMTX Gemini Therapeutics	12.90%
RXRX Recursion Pharmaceuticals	8.43%
UPXI Upexi	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable
UPXI Upexi	130	58.61 million	85.41 million	Optionable

UPXI, GMTX, RXRX, and CPRX Headlines

Recent News About These Companies

Upexi Approves Share Increase and New Agreement

August 20 at 5:51 PM | tipranks.com

Upexi (NASDAQ:UPXI) Trading Down 10% - Time to Sell?

August 17, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Short Interest Update

August 17, 2025 | marketbeat.com

Upexi (NASDAQ:UPXI) Shares Gap Down - Here's What Happened

August 16, 2025 | marketbeat.com

Upexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

Digital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4K

August 15, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?

August 15, 2025 | marketbeat.com

Former Amazon aggregator turns to Solana, records $70K in daily rewards

August 13, 2025 | msn.com

Upexi establishes Advisory Committee, welcomes Hayes as first member

August 13, 2025 | msn.com

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

August 12, 2025 | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11, 2025 | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9, 2025 | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, GMTX, RXRX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.08 +0.52 (+2.53%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$21.09 +0.01 (+0.07%)

As of 08/22/2025 08:00 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gemini Therapeutics NASDAQ:GMTX

$60.35 +0.60 (+1.00%)

As of 08/22/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.94 +0.16 (+3.35%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.01 +0.07 (+1.42%)

As of 08/22/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Upexi NASDAQ:UPXI

$7.93 +0.95 (+13.61%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.93 0.00 (0.00%)

As of 08/22/2025 07:58 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time